Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Monday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright lowered their target price on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research note on Monday, June 24th.

Aethlon Medical Stock Down 1.9 %

Shares of NASDAQ:AEMD opened at $0.39 on Monday. The company has a market capitalization of $5.35 million, a P/E ratio of -0.08 and a beta of 1.74. Aethlon Medical has a 52-week low of $0.24 and a 52-week high of $2.35. The stock’s fifty day simple moving average is $0.40 and its 200-day simple moving average is $0.70.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the previous year, the business earned ($1.30) earnings per share. On average, sell-side analysts anticipate that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.